Active Biotech management team consists of Helen Tuvesson, President & CEO, Hans Kolam, Chief Financial Officer and Erik Vahtola, Chief Medical Officer.

Helén Tuvesson

President & CEO

President & CEO since 2017
Born 1962
Shareholding: 386,157 shares

Employed by the company since 1998. Helén Tuvesson has a PhD in cell and molecular biology in medical science from Lund University. Helén has more than 25 years of experience in leading drug development in senior positions within preclinical and clinical development at Pharmacia and Active Biotech, including as Chief Scientific Officer for 6 years at Active Biotech. In this role, Helén was responsible for the operational research activities within the company as well as the company’s project portfolio in late stage clinical development in neurodegenerative diseases and cancer indications.


Helén is a board member of Mendus AB (formerly Immunicum AB).

Hans Kolam

Chief Financial Officer

Chief Financial Officer since 2000
Born 1951
Shareholding: 276,637 shares (of which 9,900 shares via related parties)

Employed by the company since 2000. Hans Kolam has a BSc in Business Administration from Uppsala University. Hans has more than 40 years of experience from the pharmaceutical industry with leading financial positions during the years 1979-2000 at Pharmacia. Hans also has extensive experience from investor relations and business development.

Erik Vahtola

Chief Medical Officer

Chief Medical Officer since 2022
Born 1976
Shareholding: 140,073 shares

Employed by the company since January, 2022. Erik is a Medical Doctor (MD) with experience from working as a specializing physician in oncology at the Helsinki University Central Hospital, Finland, and he holds a PhD in pharmacology and an MSc in cell biology from Åbo Akademi University, Finland. Erik has more than 10 years of experience altogether from regulatory authority and pharma industry positions within clinical development and medical affairs. Before joining Active Biotech, he has worked at Bayer Pharmaceuticals, Orion Corporation and Roche Pharma, Finland.